Trial Profile
Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial HoT-PE
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms HoT-PE
- 16 Nov 2021 This trial is completed in Portugal (End Date: 26 Nov 2019), according to European Clinical Trials Database record.
- 22 Oct 2020 This trial is completed in Netherland (Global End Date: 26 Nov 2019), according to European Clinical Trials Database record.
- 28 Aug 2020 Results (N=576), assessing long-term survival as well as the quality of life and its change over time following early discharge of patients with acute low-risk pulmonary embolism, published in the European Respiratory Journal